Dabrafenib (Tafinlar,Dabradx)

Dabrafenib is a highly selective BRAF serine-threonine kinase inhibitor and a precision targeted antineoplastic agent.

WhatsApp

To ensure medication safety, consult customer service for free before purchasing. Returns/exchanges are not accepted except for quality issues.

Authentic

Guarantee

Fast Delivery

Privacy

Dabrafenib Medication Guide

The FDA has approved dabrafenib for the treatment of melanoma, non-small cell lung cancer, etc.

Dabrafenib is a kinase inhibitor developed by Novartis and first received FDA approval on May 29, 2013. Dabrafenib inhibits cell growth in various BRA···【More】
Update: 03 Apr,2026Source: BigbearViews: 99
Dabrafenib Dosage and Administration: Recommended Dosage, Dosage Reduction, and Dosage Adjustment fo

Dabrafenib, a BRAF inhibitor, is approved for the treatment of various cancers, including melanoma and lung cancer. Dosage varies significantly depend···【More】
Update: 03 Apr,2026Source: BigbearViews: 89
Dabrafenib Package Insert: Indications, Dosage and Administration, Adverse Reactions

Dabrafenib is a selective BRAF serine-threonine kinase inhibitor that exerts its anti-tumor effect by specifically targeting the BRAF V600E/V600K muta···【More】
Update: 03 Apr,2026Source: BigbearViews: 87
Adverse Reactions and Side Effects of Dabrafenib

While dabrafenib provides precise targeted therapy for BRAF-mutant tumors, it is crucial to be aware of its potential multi-systemic adverse reactions···【More】
Update: 02 Apr,2026Source: BigbearViews: 112